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von Willebrand factor propeptideIn adult patients with sickle cell disease two distinct subphenotypes have previously been deﬁned: patients
with the viscosity-vaso-occlusion subphenotype (VVO) suffer mainly from vaso-occlusive pain crises and have
a relatively high hemoglobin concentration. Patients classiﬁed as the hemolysis-endothelial dysfunction
subphenotype (HED) suffer from stroke and pulmonary hypertension and have an elevated concentration of
lactate dehydrogenase. However, this classiﬁcation is not possible in children due to low rates of complications.
We used laboratory markers to classify children into the two subphenotypes, and measured vWF and vWF
propeptide as markers of endothelial dysfunction. We included 106 children with sickle cell disease (mean age
8.7 years), 74 (70%) with HbSS/HbSβ° genotype and 32 (30%) with HbSC/HbSβ+ genotype. vWF and vWF
propeptide were signiﬁcantly elevated in patients with sickle cell disease; this wasmore pronounced in patients
with the HbSS/HbSβ° genotype. Patients with the HED subphenotype had higher levels of vWF propeptide, and a
trend towards higher levels of vWF compared to thosewith the VVO subphenotype.We demonstrated that even
young children in a stable clinical condition show signs of persistent endothelial dysfunction. A prospective study
should demonstrate whether elevated levels of vWF and its propeptide are associated with an increased risk of
complications speciﬁc for the HED subphenotype.
© 2013 Elsevier Ltd. All rights reserved.Introduction
Sickle cell disease (SCD) is a heterogeneous disorder with a highly
variable clinical spectrum. To improve our understanding of the
diversity in clinical presentation, Kato et al. postulated a classiﬁcation
of two clinical subphenotypes in adult patients [1]. According to this
classiﬁcation, patients with the viscosity-vaso-occlusion subphenotype
(VVO) have a relatively high hemoglobin level and experience frequent
vaso-occlusive pain crises, acute chest syndrome and osteonecrosis. At
the other end of the spectrum are patients with the hemolysis-
endothelial dysfunction subphenotype (HED); these patients have
high levels of lactate dehydrogenase (LDH) and a high reticulocytelotype; ELISA, enzyme-linked
and 2; Hb, hemoglobin; HbF,
ysfunction subphenotype; LDH,
ng; MRA, magnetic resonance
CI, silent cerebral infarcts; TAT,
cclusion subphenotype; vWF,
Hematology, Emma Children’s
x 22660, 1100 DD Amsterdam,
draat).
ghts reserved.count and their clinical picture is characterized by stroke, pulmonary
hypertension, priapism and leg ulcers [2]. It would be useful to identify
pediatric SCD patients with the HED or VVO subphenotype to be able to
screen for these speciﬁc complications. However, it is difﬁcult to
distinguish the two subphenotypes in young patients because the rate
of complications is still low.
The exact pathophysiology of the subphenotypes remains unclear.
A reduced bioavailability of nitric oxide (NO) due to intravascular
hemolysis has been suggested to play an important role in endothelial
dysfunction and in particular in pulmonary hypertension. Whether a
decreased level of NO is a true cause of endothelial dysfunction or a
secondary phenomenon remains a subject of debate [3–5].
Von Willebrand factor (vWF) is a sensitive marker of endothelial
dysfunction. Several reports have demonstrated elevated levels of
vWF in adult patients with SCD [6–9]. The plasma concentration of
vWF is higher in patients with a severe genotype (HbSS or HbSβ°)
compared to patients with a moderate genotype (HbSC or HbSβ+) [9].
There is very limited information on vWF plasma concentration in
children with SCD. In a small study, 10 children with sickle cell disease
and nocturnal hypoxemia were found to have elevated levels of vWF
[10] but further studies on vWF in children with SCD are lacking.
vWF is released into the circulation by a constitutive pathway and a
regulated pathway. After stimulation of the endothelium, the regulated
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undergoes cleavage of its propeptide. Subsequently, both mature vWF
and its propeptide are secreted into the bloodstream. vWF propeptide
returns to baseline values within approximately 7 hours after acute
activation of the endothelium, whereas the increase of mature vWF is
longer due to a four- to ﬁvefold longer half-life [11]. Thus, in chronic
endothelial dysfunction, levels of vWF propeptide are not increased.
This was illustrated in patients with diabetes who were found to have
an elevated level of mature vWF but a normal concentration of vWF
propeptide [12].
Both mature vWF and vWF propeptide may serve as indicators of
future complications caused by endothelial dysfunction. This has been
demonstrated in a prospective study of 102 children with insulin-
dependent diabetes. A subgroup of patients developed elevated plasma
concentrations of vWF and vWF propeptide. During a two year follow
up, these children developed microalbuminuria, in contrast to the
subgroup who did not have elevated plasma concentrations of vWF
and vWF propeptide [13]. The results of this study suggest a relation
between endothelial dysfunction and nephropathy.
vWF propeptide has never been studied in patients with SCD before.
In the present study, we assessed plasma levels of vWF and its propeptide
in a large group of young children with sickle cell disease in order to
investigate endothelial dysfunction. Furthermore, we investigated
whether vWF and vWF propeptide are inﬂuenced by genotype,
haplotype or subphenotype.
Methods
Patients
All children between 2–18 years with SCD treated at the Emma
Children's Hospital of the AMC were eligible to participate in the
study. Collection of blood samples was carried out during regular visits
to the outpatient clinic when patients were in a stable clinical condition
(i.e. no vaso-occlusive crises, infections or blood transfusions 3months
prior to collection of blood samples). Patients using hydroxyurea and
those on chronic blood transfusions were excluded.
Patients with HbSS or HbSβ° were considered to have a severe
genotype and patients with HbSC or HbSβ+ a mild genotype.
The medical ethics committee approved the study protocol and
written informed consent was obtained from all participants.
Laboratory Parameters
vWF plasma concentration was measured by enzyme-linked
immunosorbent assay (ELISA) (Dakopatts) [14]. vWF propeptide was
assessed using CLB-pro, an antibody against vWF propeptide [11]. To
assess coagulation activation, prothrombin fragment 1 and 2 (F1+ 2)
was measured by ELISA using a mouse anti-human antibody [15].
Thrombin-antithrombin complex (TAT) was measured by ELISA using
a rabbit anti-human antibody (Enzygnost) [16].
Hematological parameters including hemoglobin (Hb), reticulocytes
and coagulation factor FVIII were measured. In addition, LDH was
assessed. Hemoglobin F percentage (HbF) was only measured in
children N36months to eliminate the effect of neonatal HbF.
Laboratory parameters were classiﬁed as abnormal when they were
elevated 2 standard deviations (SD) above the mean of the normal
population.
Haplotypes
Haplotype analysis of the β-globin gene cluster was performed by
high-resolution melting curve analysis, as described previously
[17,18], using the LightScanner instrument and software (LightScanner;
Idaho Technologies Inc., USA). Only patients with a severe genotype
(HbSS/HbSβ°) were included in this analysis. Central African Republic(CAR) haplotype is considered to be the most severely affected
haplotype and Benin haplotype a more moderate haplotype. Therefore
we compared patients with at least one allele of the CAR haplotype
(homozygous or heterozygous) with patients homozygous for Benin
haplotype.
Subphenotypes
In our pediatric study population the complication rate is low and
therefore it was not possible to deﬁnitely classify patients into the two
subphenotypes based on clinical events. Because a relatively high level
of hemoglobin is a characteristic of the VVO subphenotype, we classiﬁed
patients within the upper quartile of hemoglobin level as the VVO
subphenotype. Hemolysis is a hallmark of the HED subphenotype;
therefore we classiﬁed patients within the upper quartile of LDH as the
HED subphenotype. Although in adult patients with SCD, reticulocyte
count is the best parameter for hemolysis [3], in children the reticulocyte
count is highly dependent on several other factors, such as iron
deﬁciency, bone marrow depression and infection. Therefore we used
LDH as a more robust marker of hemolysis in children with SCD. To
eliminate the effect of SCD genotype on the results, only patients with
a severe genotype (HbSS/HbSβ°) were included in this analysis.
Deﬁnition of Clinical Events
Data were collected on lifetime complications. We scored admissions
for vaso-occlusive pain episodes. Stroke is deﬁned as a focal neurological
deﬁcitwith evidence onneuroimaging of a cerebral infarct corresponding
with the focal deﬁcit. Silent cerebral infarcts (SCI) are areas of increased
signal intensity on cerebral imaging (magnetic resonance imaging, MRI)
without a history or physical ﬁndings of a focal neurological deﬁcit.
Cerebral vasculopathy is deﬁned as an abnormal high blood ﬂow velocity
as assessed by transcranial Doppler ultrasonography or stenosis of an
intracerebral artery of 50% or more as assessed by magnetic resonance
angiography (MRA). Acute chest syndrome is deﬁned as a new
appearance of an inﬁltrate on chest radiograph in presence of pulmonary
symptoms. Priapism is deﬁned as a persistent and often painful penile
erection. Avascular bone necrosis of hip or shoulder is deﬁned as an
abnormality seen on radiography due to bone infarction associated with
chronic pain of the affected joint. Leg ulcers are deﬁned as painful skin
defects on (lower) legs.
Microalbuminuria
Microalbuminuria was deﬁned as an elevated albumin/creatinine
ratio (N2.5 mg albumin per mmol creatinine in men and N3.5 mg
albumin per mmol creatinine in women). In some patients, only a
urine dipstick test was performed. A positive result with urine dipstick
was always conﬁrmed by an elevated albumin/creatinine ratio.
Statistical Analyses
All presented laboratory values aremean values calculated over 1 to 3
hospital visits per patient. We used a one-sample t-test to evaluate
differences between laboratory parameters of our study group and
reference values. To test differences between 2 groups, a student's t-test
was used in normally distributed data and a Mann–Whitney U test was
used when data were not normally distributed. A Fisher’s exact test was
used to evaluate differences in complication rates between groups. To
investigate the association between blood group and levels of vWF and
vWF propeptide a one-way ANOVA was performed.
Results
We included 106 children with SCD, mean age 8.7years (range 2.0 -
17.5years); themajority (70%) had a severe genotype (HbSS or HbSβ°).
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concentrations of vWF and vWF propeptide were signiﬁcantly higher
in patients with SCD compared to the reference values (Table 1,
Fig. 1). Most patients (53%) had blood group O. vWF plasma
concentration was lower in patients with blood group O compared to
patients with blood group A, B or AB (p=0.003 by ANOVA). The levels
of vWF propeptide were not associated with blood group.
Genetic Variability
Patients with a severe genotype (HbSS or HbSβ°) had signiﬁcantly
higher concentrations of vWF and its propeptide and F1+ 2 and TAT
compared to patients with a moderate genotype (HbSC or HbSβ+)
(Table 1, Fig. 1). In patients with a severe genotype, vWF and vWF
propeptide were above the reference value in 32% and almost 24%,
respectively.
The haplotype of the β globin gene cluster is a known modiﬁer of
clinical variability in SCD. Haplotype was available in 55 patients (74%
of all patients with HbSS or HbSβ°). Most patients were homozygous
for Benin haplotype (32 patients, 58%). Second most prevalent was
CAR haplotype, with 7 homozygous patients (13%) and 5 heterozygous
patients (9%). The remaining 11 patients (20%) had miscellaneous
haplotypes (heterozygous for Benin or Senegal, Cameroon or
undetermined haplotypes).
Compared to patients with a homozygous Benin haplotype, patients
with at least one CAR haplotype had a lower leukocyte count, LDH and
FVIII (Table 2). We did not ﬁnd a difference in markers of endothelial
dysfunction or coagulation activation between these two haplotype
groups.
Subphenotypes
The comparison of the two subphenotypeswas restricted to patients
with a severe genotype (HbSS or HbSβ°) (Table 3). Agewas comparable
between VVO and HED subphenotypes (8.5 ± 5.1 years vs 7.5 ±
4.0 years, p = 0.569) as was follow up time (13.3 ± 5.1 years vs
15.4 ± 5.8 years, p = 0.383) and blood group (53% blood group O vs
62%, p = 0.718). Hospitalization rate for vaso-occlusive pain episodes
was very low and did not differ between the two subphenotypes.
Cerebral vasculopathy was present in four patients with the HED
subphenotype but in non of the patients with the VVO subphenotype.
Compared to the VVO subphenotype, patients in the HED group had
more pronounced reticulocytosis (11.5% vs 6.8%, p=0.022) and higher
leukocyte count (13.7 × 109/l vs 10.5 × 109/l, p = 0.008). vWF and its
propeptide were considerably higher in the HED group: 74 nmol/l vsTable 1
Laboratory parameters.
Total cohort (n=106) HbS
Reference value p*
Hb (g/l) 105-161 90 ±16 b0.001 81
HbF (%) b1% 8.2 (3.9 – 14.0) b0.001 9.0*
Reticulocytes (%) 0.5-2.5 7.4 ±4.8 b0.001 8.8*
Leukocytes (x109/l) 4.6-13.5 10.3 ±3.8 0.002 12.0
Platelets (x109/l) 150-350 366 ±131 b0.001 412
LDH (U/l) 0-323 485 ±183 b0.001 547
vWF (nmol/l) 25 – 74 68 ±24 b0.001 72
vWF pro (nmol/l) 2.8 – 8.3 7.1 ±2.2 b0.001 7.5
vWF ratio n.a. 0.108 ±0.026 n.a. 0.10
FVIII (%) 50-150 238 ±82 b0.001 263
TAT (μg/l) 0-4.6 8.8 (5.3 – 13.7) b0.001 9.3*
F1+ 2 (nmol/l) 0.3-1.6 0.7 (0.5 – 0.9) 0.606 0.8*
Data is presented as mean± standard deviation or median (25th to 75th percentile).
F1+ 2, prothrombin fragment 1 and 2; FVIII, factor VIII; Hb, hemoglobin; HbF, hemoglobin F;
factor.
*compared to reference values. # HbSS/HbSβ° vs HbSC/HbSβ+.57nmol/l, p=0.104 and 7.6nmol/l vs 6.0nmol/l, p=0.008, respectively
(Table 3).
Microalbuminuria
In the total cohort, 17% of patients had micoralbuminuria (19% of
patients with HbSS or HbSβ° and 13% of patients with HbSC or
HbSβ+). In patients with a severe genotype, there was a trend towards
a higher vWF propeptide in patients who had microalbuminuria
compared to patients who did not have microalbuminuria (8.5 nmol/l
vs 7.3nmol/l, p=0.068). There was also trend towards a higher plasma
concentration of vWF in (78 nmol/l vs 70 nmol/l, p = 0.130). Also in
patients with a mild genotype, there was a trend towards a higher
vWF propeptide in patients who had microalbuminuria compared to
patients who did not have microalbuminuria (4.4 nmol/l vs 6.5 nmol/l,
p=0.062).
Discussion
Despite the young age and the stable clinical condition at the time of
testing, we found an abnormal high plasma concentration of vWF and
vWF propeptide in our patients. This was more pronounced in patients
with a severe genotype and in patients in the HED subphenotype.
This is the ﬁrst large study to evaluate vWF and vWF propeptide in
young children with sickle cell disease. vWF is directly involved in
adhesion of sickle red blood cells to the endothelium and is a promising
parameter of endothelial dysfunction to study in SCD [19].
Even in the absence of clinical signs of vaso-occlusion or infection,
we found an elevated concentration of vWF propeptide, although not
of the same magnitude as previously described in the context of acute
illness [12]. This indicates that some form of persistent endothelial
activation is present in our patients. vWF propeptide is overwhelmingly
elevated in the context of acute severe illness, e.g. malaria, sepsis and
thrombotic thrombocytopenic purpura. Previous studies on small
groups of adult patients with chronic vascular diseases (i.e. chronic
kidney disease and ischemic heart disease) demonstrated an elevated
level of vWF propeptide, reﬂecting continuous acute endothelial
activation [20–24]. Our results show that a subgroup of children (24%)
with a severe genotype has elevated levels of vWF propeptide
(Fig. 1B). Whether the elevated concentration of vWF propeptide in
this group of patients could potentially predict speciﬁc complications
in SCD and therefore indentify patients with a HED subphenotype
should be studied further. We did ﬁnd an association between vWF
propeptide andmicoralbuminuria, but due to the cross sectional design
of our study, we could not investigate the time relation between
endothelial dysfunction and micoralbuminuria.S/HbSβ° (n=74) HbSC/HbSβ+ (n=32)
p* p* p#
±10 b0.001 109 ±9 b0.001 b0.001
(5.8 – 15.5) b0.001 2.8* (1.3 - 5.9) 0.039 b0.001
(6.5 – 12.2) b0.001 2.7* (2.0 – 3.4) b0.001 b0.001
* (9.0 – 13.7) b0.001 7.1* (5.1 – 8.9) 0.024 b0.001
±120 b0.001 268 ±97 0.300 b0.001
* (443 – 634) b0.001 301* (267 – 344) b0.001 b0.001
±24 b0.001 59 ±21 0.025 0.011
±2.3 b0.001 6.1 ±1.6 0.118 0.008
5 ±0.025 n.a. 0.114 ±0.030 n.a. 0.191
±82 b0.001 181 ±49 b0.001 b0.001
(6.4 – 14.7) b0.001 5.9* (4.6 – 9.5) 0.002 0.015
(0.5 – 0.9) 0.020 0.5* (0.4 – 0.8) 0.742 0.006
LDH, lactate dehydrogenase; TAT, thrombin-antithrombin complex; vWF, von Willebrand
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Fig. 1. Distribution of vonWillebrand factor (vWF) and vWF propeptide. vWF (A) and vWF propeptide (B) in all patients, patients with a severe genotype (HbSS or HbSβ°) and patients
with amild genotype (HbSC or HbSβ+). vWF (C) and vWF propeptide (D) in patients homozygous or heterozygous for Central African Republic (CAR) haplotype or homozygous for Benin
haplotype (BEN). vWF (E) andvWFpropeptide (F) in viscosity-vaso-occlusion subphenotype (VVO) and hemolysis-endothelial dysfunction subphenotype (HED). Grey area: normal range
of vWF or vWF propeptide (2 standard deviations above and below mean of normal population). Error bars represent mean± standard deviation.
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genotype, haplotype and subphenotype. The increase in vWF and vWF
propeptide was more pronounced in patients with a severe genotype
(HbSS or HbSβ°) compared to patients with a moderate genotype
(HbSC or HbSβ+). The elevated concentration of vWF in patients with
a severe genotype was found previously in a study in adults by Mohan
et al. [9] and a study by Nur et al. [8], although this did not reach
statistical signiﬁcance in the latter study.
Our analysis of the association between haplotype and endothelial
dysfunction was limited by lack of power, due to the lack of variation in
haplotype within the study. There are no previous studies that haveanalyzed the association between haplotype and endothelial dysfunction.
Prior studies on hematological differences between haplotypes are
difﬁcult to interpret because of conﬂicting results.
Patients with the HED subphenotype have a higher concentration
vWF propeptide and a trend towards an elevated concentration of
mature vWF, compared to patients with the VVO subphenotype. Chronic
hemolysis, the hallmark ot the HED subphenotype, is associated with
endothelial dysfunction although the exact mechanism remains unclear.
Previous observations suggest that intravascular hemolysis leads to
elevated plasma levels of cell free hemoglobin which produces reactive
oxygen species. This results in scavenging of NO. In addition, hemolysis
Table 2
Endothelial dysfunction according to haplotype in patients with a severe genotype (HbSS
or HbSβ°).
CAR (n=12) BEN (n=32) p
Hb (g/l) 77 (69 – 82) 79 (74 – 86) 0.128
HbF (%) 11.7 (6.5 – 16.0) 9.8 (5.8 – 15.4) 0.610
Reticulocytes (%) 10.1 (5.9 – 13.8) 9.0 (6.3 – 10.9) 0.282
Leukocytes (x109/l) 10.8 (6.0 – 12.7) 12.4 (9.5 – 14.1) 0.050
Platelets (x109/l) 375 (246 – 456) 433 (359 – 511) 0.074
LDH (U/l) 438 (402 – 542) 553 (469 – 660) 0.030
vWF (nmol/l) 61 (49 – 75) 72 (58 – 94) 0.223
vWF pro (nmol/l) 6.8 (5.9 – 7.5) 7.5 (6.3 – 9.7) 0.183
vWF ratio 0.108 (0.088 – 0.128) 0.102 (0.087 – 0.115) 0.804
FVIII (%) 225 (153 – 276) 278 (242 – 334) 0.014
TAT (μg/l) 8.5 (4.9 – 21.0) 9.5 (7.6 – 14.7) 0.403
F1+2 (nmol/l) 0.64 (0.56 – 0.82) 0.83 (0.54 – 1.07) 0.413
Data is presented as median (25th to 75th percentile).
BEN, homozygous for Benin haplotype; CAR, homozygous or heterozygous for Central
African Republic haplotype; F1 + 2, prothrombin fragment 1 and 2; FVIII, factor VIII;
Hb, hemoglobin; HbF, hemoglobin F; LDH, lactate dehydrogenase; TAT, thrombin-
antithrombin complex; vWF, von Willebrand factor.
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arginine and reduces the availability of substrate for NO production.
The reduced bioavailability of NO may result in endothelial activation,
enhanced expression of cell adhesion molecules and coagulation
activation. However, as stated before, whether a decreased availability
of NO is the true cause of endothelial dysfunction or a mere side effect
remains unclear.Table 3
Subphenotypes in patients with a severe genotype (HbSS/HbSβ°).
VVO (n = 15) HED (n = 13) p
Hb (g/l) 94 (92–98) 73 (68–79) <0.001
LDH (U/l) 482 (293–574) 747 (669–787) <0.001
Clinical events
Vaso-occlusive events (number of
events per patient/years of FUP)
0.11 (0.00–0.33) 0.16 (0.00–0.23) 0.569
Stroke 0 1 0.464
Silent cerebral infarct (affected
patients/patients with available
imaging)
3/8 (38%) 6/9 (67%) 0.347
Cerebral vasculopathy 0 4 0.035
Acute Chest Syndrome (number of
patientswith ≥ 1 episode) 4 6 0.433
Priapism (affected boys/total boys) 0/8 1/9 1.000
Avascular bone necrosis (affected
patients) 2 0 0.484
Leg ulcers (affected patients) 0 0 1.000
Laboratory parameters
HbF (%) 11.4 (7.2–19.5) 7.5 (4.6–10.0) 0.143
Reticulocytes (%) 6.8 ± 2.5 11.5 ± 5.6 0.022
Leukocytes (x109/l) 10.5 ± 2.9 13.7 ± 2.7 0.008
Platelets (x109/l) 373 (319–517) 451 (267–482) 0.897
vWF (nmol/l) 57 (50–76) 74 (59–96) 0.104
vWF pro (nmol/l) 6.0 (4.8–6.7) 7.6 (6.8–10.0) 0.008
vWF ratio 0.104 ± 0.023 0.110 ± 0.020 0.541
FVIII (%) 215 ± 64 306 ± 77 0.003
TAT (μg/l) 8.2 (4.4–11.3) 12.3 (9.3–26.0) 0.061
F1+2 (nmol/l) 0.9 (0.6–0.9) 0.7 (0.5–1.0) 0.918
Data is presented as mean± standard deviation or median (25th to 75th percentile).
F1+ 2, prothrombin fragment 1 and 2; FVIII, factor VIII; FUP, follow up; Hb, hemoglobin;
HbF, hemoglobin F; HED, hemolysis-endothelial dysfunction subphenotype; LDH, lactate
dehydrogenase; TAT, thrombin-antithrombin complex; VVO, viscosity-vaso-occlusion
phenotype; vWF, von Willebrand factor.As vWF propeptide is considerably higher in the HED subphenotype,
our results suggest that vWF propeptide is a potential predictor of
subphenotype in young children. Our analysis was hampered by low
complication rates in our young patient cohort (Table 3). The admission
rate for vaso-occlusive pain episodes was very low, probably because
most pain episodes are treated at home. However cerebral vasculopathy,
a distinct feature of the HED subphenotype, was present in childrenwith
the HED subphenotype and not in patients with the VVO subphenotype
(p = 0.035). A prospective study should determine whether elevated
levels of vWF propeptide precede speciﬁc complications seen in patients
with the HED subphenotype, for example stroke and pulmonary
hypertension, and whether it can be used to target speciﬁc screening
for these complications.
In summary, we demonstrated that even young children during
stable clinical condition demonstrate signs of persistent endothelial
dysfunction; this is more distinct in patients with a severe genotype
and in patients classiﬁed as the HED subphenotype. A prospective
study should demonstrate whether elevated levels of vWF and vWF
propeptide predict an increased risk of complications speciﬁc for the
HED subphenotype.
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